Juliana Monte Real
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juliana Monte Real has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Marcelo Antonini
Hospital do Servidor Público Estadual
14 shared publications - André Mattar
Women Hospital, São Paulo, Brazil
13 shared publications - Reginaldo Guedes Coelho Lopes
Hospital do Servidor Público Estadual Francisco Morato de Oliveira, São Paulo, Brazil
12 shared publications - Odair Ferraro
Hospital do Servidor Público Estadual
10 shared publications - Luiz Henrique Gebrim
Hospital Beneficência Portuguesa, São Paulo, São Paulo, Brazil
9 shared publications - Gabriel Duque Pannain
Instituto de Assistência Médica ao Servidor Público Estadual de São Paulo, Brazil
7 shared publications
Latest Publications
- Open Access
- 12 July 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-12
Is axillary surgery still justified in DCIS diagnosed via vacuum-assisted biopsy?
The role of axillary surgery in ductal carcinoma in situ (DCIS) remains controversial, particularly for cases diagnosed via vacuum-assisted biopsy (VAB), which may reduce “upstage” to invasive disease. This study evaluates the incidence of axillary metastasis and pathologic upstaging in DCIS to identify subgroups where axillary staging can be safely omitted. A retrospective cohort of 494 patients with pure DCIS diagnosed by VAB (2011–2019) was analyzed. Patients were stratified by age, nuclear grade, comedonecrosis, and surgical approach (breast-conserving surgery [BCS] vs. mastectomy). Axillary management included sentinel node biopsy (SNB), axillary dissection (AD), or omission. Multivariate logistic regression identified predictors of axillary surgery and upstaging to invasive carcinoma. Most patients underwent BCS (72.7%), with axillary evaluation performed in 35.1% of BCS cases versus 91.9% of mastectomies (p < 0.001). Only 3.8% (19/494) were upstaged to invasive carcinoma, and nodal involvement occurred in 1.2% (3/250) of axillary procedures—all in patients with invasive foci on final pathology. No pure DCIS cases had nodal metastasis. Younger age (< 40 years, p = 0.039), high nuclear grade (grade 3, p = 0.006), and mastectomy (p < 0.001) independently predicted axillary surgery. Comedonecrosis and palpable lesions were associated with higher SNB rates but not nodal positivity. Routine axillary surgery is unnecessary in VAB-diagnosed DCIS. Omission of SNB appears safe for patients undergoing BCS without high-risk features (palpability, high grade). Axillary staging may be reserved for mastectomy candidates or those with suspicions imaging of invasive disease.
- 12 July 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-12
Open AccessIs axillary surgery still justified in DCIS diagnosed via vacuum-assisted biopsy?
The role of axillary surgery in ductal carcinoma in situ (DCIS) remains controversial, particularly for cases diagnosed via vacuum-assisted biopsy (VAB), which may reduce “upstage” to invasive disease. This study evaluates the incidence of axillary metastasis and pathologic upstaging in DCIS to identify subgroups where axillary staging can be safely omitted. A retrospective cohort of 494 patients with pure DCIS diagnosed by VAB (2011–2019) was analyzed. Patients were stratified by age, nuclear grade, comedonecrosis, and surgical approach (breast-conserving surgery [BCS] vs. mastectomy). Axillary management included sentinel node biopsy (SNB), axillary dissection (AD), or omission. Multivariate logistic regression identified predictors of axillary surgery and upstaging to invasive carcinoma. Most patients underwent BCS (72.7%), with axillary evaluation performed in 35.1% of BCS cases versus 91.9% of mastectomies (p < 0.001). Only 3.8% (19/494) were upstaged to invasive carcinoma, and nodal involvement occurred in 1.2% (3/250) of axillary procedures—all in patients with invasive foci on final pathology. No pure DCIS cases had nodal metastasis. Younger age (< 40 years, p = 0.039), high nuclear grade (grade 3, p = 0.006), and mastectomy (p < 0.001) independently predicted axillary surgery. Comedonecrosis and palpable lesions were associated with higher SNB rates but not nodal positivity. Routine axillary surgery is unnecessary in VAB-diagnosed DCIS. Omission of SNB appears safe for patients undergoing BCS without high-risk features (palpability, high grade). Axillary staging may be reserved for mastectomy candidates or those with suspicions imaging of invasive disease.
- Open Access
- 20 March 2025
- Published by Elsevier in The Breast
- Vol. 81, 104453
CADONOT: Comparing axillary dissection or not in breast cancer surgery
- 20 March 2025
- Published by Elsevier in The Breast
- Vol. 81, 104453
Open AccessCADONOT: Comparing axillary dissection or not in breast cancer surgery
- Open Access
- 20 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
The relationship between body mass index and pathological complete response in Brazilian breast cancer patients
Body mass index (BMI) is a key factor in the progression of breast cancer (BC), with conflicting evidence on its influence on pathological complete response (pCR) following neoadjuvant chemotherapy (NAC). Despite these global findings, studies focusing on real-world Brazilian data remain scarce. This study aimed to evaluate the impact of BMI on pCR rates, recurrence-free survival (RFS), and overall survival (OS) in Brazilian women with BC treated with NAC. A retrospective cohort of 1,751 patients with stage I–III invasive primary BC treated between January 2011 and December 2020 at two public healthcare centers Hospital Pérola Byington (HPB) and Hospital do Servidor Público Estadual (HSPE) in Brazil was analyzed. Data included BMI categories (normal, overweight, and obese) and their associations with pCR, RFS, and OS outcomes. Obesity was prevalent (35.5%) among the cohort, with most patients being postmenopausal (50.9%). Tumors were predominantly stage III invasive ductal carcinoma, with triple-negative and luminal B subtypes being the most common. Radical surgery was performed in 79.8% of cases, achieving a pCR rate of 22.3%, and 30.9% of patients experienced recurrence, predominantly systemic (27.7%). No significant differences in pCR, RFS, or OS were observed across BMI categories. BMI was not associated with pCR, RFS, or OS in this large Brazilian cohort, highlighting the need for further studies to explore BMI dynamics during treatment and its potential influence on therapeutic outcomes. Future investigations in diverse healthcare settings may provide additional insights into optimizing breast cancer management across BMI strata.
- 20 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessThe relationship between body mass index and pathological complete response in Brazilian breast cancer patients
Body mass index (BMI) is a key factor in the progression of breast cancer (BC), with conflicting evidence on its influence on pathological complete response (pCR) following neoadjuvant chemotherapy (NAC). Despite these global findings, studies focusing on real-world Brazilian data remain scarce. This study aimed to evaluate the impact of BMI on pCR rates, recurrence-free survival (RFS), and overall survival (OS) in Brazilian women with BC treated with NAC. A retrospective cohort of 1,751 patients with stage I–III invasive primary BC treated between January 2011 and December 2020 at two public healthcare centers Hospital Pérola Byington (HPB) and Hospital do Servidor Público Estadual (HSPE) in Brazil was analyzed. Data included BMI categories (normal, overweight, and obese) and their associations with pCR, RFS, and OS outcomes. Obesity was prevalent (35.5%) among the cohort, with most patients being postmenopausal (50.9%). Tumors were predominantly stage III invasive ductal carcinoma, with triple-negative and luminal B subtypes being the most common. Radical surgery was performed in 79.8% of cases, achieving a pCR rate of 22.3%, and 30.9% of patients experienced recurrence, predominantly systemic (27.7%). No significant differences in pCR, RFS, or OS were observed across BMI categories. BMI was not associated with pCR, RFS, or OS in this large Brazilian cohort, highlighting the need for further studies to explore BMI dynamics during treatment and its potential influence on therapeutic outcomes. Future investigations in diverse healthcare settings may provide additional insights into optimizing breast cancer management across BMI strata.
- Open Access
- 14 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Circulating extracellular vesicles as potential biomarkers and mediators of acute respiratory distress syndrome in sepsis
The early sequence of respiratory failure events after the onset of sepsis is still unknown. We hypothesize that the lung should signal through circulating extracellular vesicles (EVs) when it is affected by a systemic inflammatory response. Blood samples were obtained from septic patients with (n = 5) and without acute respiratory distress syndrome (ARDS) (n = 13) at 24 h of intensive care unit admission and 3 days later at Sírio-Libanês Hospital. Pulmonary-originated sepsis was not considered. The characteristics of the plasma-isolated EVs were compatible with exosomes. 48 miRNAs were evaluated by real-time PCR. Comparing all samples from patients with sepsis + ARDS to sepsis only, 9 miRNAs are transported in smaller amounts: miR-766 (-35.7, p = 0.002), miR-127 (-23.8, p = 0.001), miR-340 (-13.5, p = 0.006), miR-29b (-12.8, p = 0.001), miR-744 (-7.1, p = 0.05), miR-618 (-4.0, p = 0.02), miR-598 (-3.8, p = 0.035), miR-1260 (-2.5, p = 0.035); and miR-885-5p is expressed at higher levels (9.5; p = 0.028). In paired samples, the set of altered miRNAs is generally different (p < 0.05) between sepsis + ARDS (miR-1183,-1267,-1290,-17,-192,-199a-3p,-25,-485-3p,-518d,-720) or sepsis only (miR-148a,-193a-5p,-199a-3p,-222,-25,-340,744). Bioinformatic analysis showed that when sepsis is associated with ARDS, those differentially expressed miRNAs potentially target messenger RNAs from the Glycoprotein VI/GP6 signaling pathway. Circulating EV-miRNA cargo could be potential biomarkers of lung inflammation during sepsis in patients requiring mechanical ventilation.
- 14 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessCirculating extracellular vesicles as potential biomarkers and mediators of acute respiratory distress syndrome in sepsis
The early sequence of respiratory failure events after the onset of sepsis is still unknown. We hypothesize that the lung should signal through circulating extracellular vesicles (EVs) when it is affected by a systemic inflammatory response. Blood samples were obtained from septic patients with (n = 5) and without acute respiratory distress syndrome (ARDS) (n = 13) at 24 h of intensive care unit admission and 3 days later at Sírio-Libanês Hospital. Pulmonary-originated sepsis was not considered. The characteristics of the plasma-isolated EVs were compatible with exosomes. 48 miRNAs were evaluated by real-time PCR. Comparing all samples from patients with sepsis + ARDS to sepsis only, 9 miRNAs are transported in smaller amounts: miR-766 (-35.7, p = 0.002), miR-127 (-23.8, p = 0.001), miR-340 (-13.5, p = 0.006), miR-29b (-12.8, p = 0.001), miR-744 (-7.1, p = 0.05), miR-618 (-4.0, p = 0.02), miR-598 (-3.8, p = 0.035), miR-1260 (-2.5, p = 0.035); and miR-885-5p is expressed at higher levels (9.5; p = 0.028). In paired samples, the set of altered miRNAs is generally different (p < 0.05) between sepsis + ARDS (miR-1183,-1267,-1290,-17,-192,-199a-3p,-25,-485-3p,-518d,-720) or sepsis only (miR-148a,-193a-5p,-199a-3p,-222,-25,-340,744). Bioinformatic analysis showed that when sepsis is associated with ARDS, those differentially expressed miRNAs potentially target messenger RNAs from the Glycoprotein VI/GP6 signaling pathway. Circulating EV-miRNA cargo could be potential biomarkers of lung inflammation during sepsis in patients requiring mechanical ventilation.
- Open Access
- 13 February 2025
- Published by Elsevier in The Breast
- Vol. 80, 104417
Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: A prognostic analysis based on real-world data comparing Brazil's public and private healthcare systems
- 13 February 2025
- Published by Elsevier in The Breast
- Vol. 80, 104417
Open AccessDisparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: A prognostic analysis based on real-world data comparing Brazil's public and private healthcare systems
- Open Access
Assessment of the relationship between metabolic syndrome and breast cancer
Introduction: Metabolic syndrome (MS) affects approximately 30% of women aged over 50 years. It is known to have a direct relationship with carcinogenesis and, therefore, with breast neoplasia. Methods: Retrospective longitudinal observational cohort study carried out at the Gynecology and Obstetrics Service of the São Paulo State Public Servant Hospital. The rates of local recurrence, distant metastases and overall survival of patients with malignant breast neoplasia in each group were evaluated. Results: Between 2017 and 2020, 375 patients underwent surgical treatment for breast cancer, of which 335 were eligible for the study, with an average age of 63.4 years old. MS is present in 32.5% of patients. Regarding the prognostic factor, patients with MS have a very similar distribution. The molecular profile in patients with MS is 39.4% of Luminal A patients, while in those without MS it is 42.5% of Luminal B. Regarding clinical staging, patients with MS have initial clinical stage I and IIA in 54 .1% of cases, while patients without MS present an initial clinical stage in 65% of cases. The average overall survival of the sample was 37.3 years, with a CI of 1.1 years; disease-free survival was 35.9 years, with CI 1.2 years; and invasive disease-free survival was 36.9 years, with CI 1.3 years. Conclusions: The presence of MS at diagnosis does not worsen survival.
Open AccessAssessment of the relationship between metabolic syndrome and breast cancer
Introduction: Metabolic syndrome (MS) affects approximately 30% of women aged over 50 years. It is known to have a direct relationship with carcinogenesis and, therefore, with breast neoplasia. Methods: Retrospective longitudinal observational cohort study carried out at the Gynecology and Obstetrics Service of the São Paulo State Public Servant Hospital. The rates of local recurrence, distant metastases and overall survival of patients with malignant breast neoplasia in each group were evaluated. Results: Between 2017 and 2020, 375 patients underwent surgical treatment for breast cancer, of which 335 were eligible for the study, with an average age of 63.4 years old. MS is present in 32.5% of patients. Regarding the prognostic factor, patients with MS have a very similar distribution. The molecular profile in patients with MS is 39.4% of Luminal A patients, while in those without MS it is 42.5% of Luminal B. Regarding clinical staging, patients with MS have initial clinical stage I and IIA in 54 .1% of cases, while patients without MS present an initial clinical stage in 65% of cases. The average overall survival of the sample was 37.3 years, with a CI of 1.1 years; disease-free survival was 35.9 years, with CI 1.2 years; and invasive disease-free survival was 36.9 years, with CI 1.3 years. Conclusions: The presence of MS at diagnosis does not worsen survival.
- Open Access
- 7 October 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0760
Knowledge related to breast cancer screening programs by physicians in Brazil
Highlights Variability in screening protocols: only 42.8% of gynecologists and obstetricians follow the 40-74 years protocol, while 76.6% of family physicians follow the 50-69 years protocol. High rate of incorrect BIRADS™ interpretation: there were 46.3% incorrect responses among gynecologists and obstetricians and 77.9% among family physicians, highlighting significant knowledge gaps. Misconception about breast ultrasound: 39.1% of gynecologists and obstetricians and 20.3% of family physicians incorrectly consider ultrasound as a screening method. Impact of inadequate training: inadequate training leads to improper
- 7 October 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0760
Open AccessKnowledge related to breast cancer screening programs by physicians in Brazil
Highlights Variability in screening protocols: only 42.8% of gynecologists and obstetricians follow the 40-74 years protocol, while 76.6% of family physicians follow the 50-69 years protocol. High rate of incorrect BIRADS™ interpretation: there were 46.3% incorrect responses among gynecologists and obstetricians and 77.9% among family physicians, highlighting significant knowledge gaps. Misconception about breast ultrasound: 39.1% of gynecologists and obstetricians and 20.3% of family physicians incorrectly consider ultrasound as a screening method. Impact of inadequate training: inadequate training leads to improper
- Open Access
Impact of neoadjuvant chemotherapy in the surgical treatment of breast cancer
Introduction: Neoadjuvant chemotherapy is an increasingly frequent option in the treatment of breast cancer. One of the goals of neoadjuvant chemotherapy is to change the indication for a mastectomy to a conservative surgery, and for axillary lymphadenectomy to sentinel lymph node assessment. Methods: This was an observational, cross-sectional, retrospective study that evaluated response to neoadjuvant chemotherapy in breast cancer patients undergoing surgical treatment. Patients were divided into three groups when the surgery indication was changed after neoadjuvant chemotherapy: downgrade, unchanged, upgrade. Results: During the study period, 355 patients were included with a mean age of 55 years. Neoadjuvant chemotherapy promoted a downgrade in 38.7% of patients with indication for mastectomy and an upgrade in 36.8% of patients with indication for conservative surgery; in the total group, the maintenance of indication for surgery was 62,2%. In the axillary approach, lymphadenectomy downgrade was 6.9% and sentinel lymph node biopsy upgrade was 34% with 27% being due to positivity and 7% due to disease progression. Multivariate analysis found a significant difference between clinical staging and change in surgical indication for both breast and axilla (p<0.0001). In the multivariate analysis of pathologic complete response and change of indication for breast and axilla surgery, triple negative and HER-2-positive tumors showed a significant difference (p<0.0001). Conclusions: Neoadjuvant chemotherapy was able to perform a downgrade of breast and axilla surgery in few patients and there was no relationship between the change of indication and pathologic complete response
Open AccessImpact of neoadjuvant chemotherapy in the surgical treatment of breast cancer
Introduction: Neoadjuvant chemotherapy is an increasingly frequent option in the treatment of breast cancer. One of the goals of neoadjuvant chemotherapy is to change the indication for a mastectomy to a conservative surgery, and for axillary lymphadenectomy to sentinel lymph node assessment. Methods: This was an observational, cross-sectional, retrospective study that evaluated response to neoadjuvant chemotherapy in breast cancer patients undergoing surgical treatment. Patients were divided into three groups when the surgery indication was changed after neoadjuvant chemotherapy: downgrade, unchanged, upgrade. Results: During the study period, 355 patients were included with a mean age of 55 years. Neoadjuvant chemotherapy promoted a downgrade in 38.7% of patients with indication for mastectomy and an upgrade in 36.8% of patients with indication for conservative surgery; in the total group, the maintenance of indication for surgery was 62,2%. In the axillary approach, lymphadenectomy downgrade was 6.9% and sentinel lymph node biopsy upgrade was 34% with 27% being due to positivity and 7% due to disease progression. Multivariate analysis found a significant difference between clinical staging and change in surgical indication for both breast and axilla (p<0.0001). In the multivariate analysis of pathologic complete response and change of indication for breast and axilla surgery, triple negative and HER-2-positive tumors showed a significant difference (p<0.0001). Conclusions: Neoadjuvant chemotherapy was able to perform a downgrade of breast and axilla surgery in few patients and there was no relationship between the change of indication and pathologic complete response
- Open Access
Integrative review of clinical trials and meta-analysis of the main studies of neoadjuvant chemotherapy in the treatment of breast cancer in the past 30 years
Neoadjuvant chemotherapy (NAC) has become a common treatment strategy for early-stage breast cancer. In this study, we conducted a systematic research in the PubMed database using the following terms: breast cancer, neoadjuvant chemotherapy, randomized clinical trials, complete pathological response, overall survival, and disease-free survival. The research has been limited to articles published in the past 30 years (1993–2023). We included only randomized clinical trials that evaluated the use of NAC in breast cancer and data on PCR rates and survival outcomes. Our research resulted in a total of 13 randomized clinical trials and two meta-analyses. The PCR rates ranged from 13% to 58%, with higher rates observed in patients with triple-negative breast cancer (TNBC) and human epidermal growth factor 2 (HER-2+) disease. Several trials reveal a significant association between PCR and better survival results, including overall survival and disease-free survival. However, the impact of PCR on survival results was less consistent in patients with hormone receptor-positive breast cancer. The use of taxanes in combination with anthracyclines has been the most common NAC scheme evaluated in these trials. The PCR rates have been associated with better survival outcomes, in patients with TNBC and HER-2+ disease. However, the impact of PCR on survival outcomes in patients with hormone receptor-positive breast cancer is less clear. Additional studies are needed to determine the optimal NAC regimen for each subtype of breast cancer and to identify biomarkers that can predict the NAC response.
Open AccessIntegrative review of clinical trials and meta-analysis of the main studies of neoadjuvant chemotherapy in the treatment of breast cancer in the past 30 years
Neoadjuvant chemotherapy (NAC) has become a common treatment strategy for early-stage breast cancer. In this study, we conducted a systematic research in the PubMed database using the following terms: breast cancer, neoadjuvant chemotherapy, randomized clinical trials, complete pathological response, overall survival, and disease-free survival. The research has been limited to articles published in the past 30 years (1993–2023). We included only randomized clinical trials that evaluated the use of NAC in breast cancer and data on PCR rates and survival outcomes. Our research resulted in a total of 13 randomized clinical trials and two meta-analyses. The PCR rates ranged from 13% to 58%, with higher rates observed in patients with triple-negative breast cancer (TNBC) and human epidermal growth factor 2 (HER-2+) disease. Several trials reveal a significant association between PCR and better survival results, including overall survival and disease-free survival. However, the impact of PCR on survival results was less consistent in patients with hormone receptor-positive breast cancer. The use of taxanes in combination with anthracyclines has been the most common NAC scheme evaluated in these trials. The PCR rates have been associated with better survival outcomes, in patients with TNBC and HER-2+ disease. However, the impact of PCR on survival outcomes in patients with hormone receptor-positive breast cancer is less clear. Additional studies are needed to determine the optimal NAC regimen for each subtype of breast cancer and to identify biomarkers that can predict the NAC response.